Ketasma is a branded form of ketotifen fumarate, an oral antihistamine and mast cell stabilizer used to help prevent allergic asthma symptoms and relieve persistent allergy conditions such as allergic rhinitis, chronic urticaria, and atopic tendencies. By blocking H1 receptors and stabilizing mast cells, Ketasma reduces histamine release and airway reactivity. It is designed for prevention, not for acute asthma attacks or sudden wheezing. Typical adult dosing is 1 mg twice daily with food; drowsiness can occur early and often lessens over time. Always follow clinician advice, especially if pregnant, nursing, or taking other medicines that cause sedation or alcohol.
Ketasma contains ketotifen fumarate, a non-competitive H1 antihistamine with mast cell–stabilizing properties. It is used as prophylaxis to decrease the frequency and intensity of allergic asthma symptoms and to support control of chronic allergic conditions such as allergic rhinitis, atopic tendencies, and chronic urticaria. By inhibiting histamine activity and stabilizing mast cells, Ketasma helps reduce late-phase allergic responses that contribute to airway hyperreactivity.
Important: Ketasma is not a rescue medicine. It does not relieve acute bronchospasm, sudden wheezing, or an ongoing asthma attack. Its benefits build gradually over several weeks of consistent use, and it is typically used alongside a broader asthma or allergy management plan, which may include inhaled corticosteroids, bronchodilators, trigger control, and allergen immunotherapy as advised by a healthcare professional.
Adults and adolescents: The commonly used oral dose is 1 mg twice daily, taken with meals to minimize gastrointestinal upset and early drowsiness. Some clinicians start with 0.5 mg twice daily for the first several days and then increase to 1 mg twice daily to improve tolerability. Because Ketasma is preventive, consistency matters—take it at the same times each day.
Pediatric dosing (general guidance): For children 3 years and older, 1 mg twice daily is commonly used. For infants and toddlers 6 months to 3 years, some guidelines reference 0.05 mg/kg twice daily. Pediatric dosing must be individualized by a clinician based on age, weight, and clinical response. Drowsiness and irritability may appear early and typically lessen with time.
Clinical use notes: Do not use Ketasma to treat sudden breathing problems—use your fast-acting inhaler and seek care as directed. If you are taking inhaled or oral corticosteroids, do not stop them abruptly; any reduction should be supervised and tapered by a clinician. It can take 2–4 weeks to appreciate benefit, with maximal effect sometimes requiring 8–12 weeks of steady therapy.
Sedation and cognition: Drowsiness, slowed reaction time, and dizziness are common early in therapy. Avoid driving, operating machinery, or activities requiring full alertness until you know how Ketasma affects you. Alcohol and other central nervous system (CNS) depressants can intensify sedation—limit or avoid these combinations.
Medical conditions and populations: Use caution if you have a history of seizures, as ketotifen may lower the seizure threshold. People with diabetes who use oral antidiabetic agents should be monitored for rare, reversible thrombocytopenia; report unusual bruising, bleeding, or pinpoint red spots on the skin. If you have liver or kidney impairment, discuss whether dose adjustments or closer monitoring are appropriate. In pregnancy, particularly the first trimester, use only if the potential benefit justifies the potential risk; data in breastfeeding are limited, and antihistamines may pass into milk—seek individualized advice. In children, early drowsiness or irritability may occur; caregivers should monitor behavior and school performance during initiation.
Do not take Ketasma if you have a known hypersensitivity to ketotifen or any tablet components. Ketasma is not appropriate as the sole therapy for acute asthma exacerbations and should never replace a fast-acting bronchodilator in emergencies. Individuals with active seizure disorders or a history of significant reactions to antihistamines should avoid use unless a clinician confirms that benefits outweigh risks and provides close supervision. Always review your full medical history and medication list with a healthcare professional before starting therapy.
Common, usually mild: Drowsiness, fatigue, dizziness, dry mouth, nausea, mild stomach upset, increased appetite, and weight gain are the most frequently reported. Many of these effects lessen after 1–2 weeks as your body adjusts. Taking doses with food and scheduling the evening dose closer to bedtime may improve tolerability.
Less common to rare: Irritability or nervousness (more often in children), sleep disturbances, headache, and mild rash can occur. Rare but important reactions include thrombocytopenia (manifesting as unusual bruising, bleeding gums, nosebleeds, or tiny red skin spots), elevated liver enzymes or hepatitis-like symptoms (persistent fatigue, abdominal pain, dark urine, jaundice), and severe allergic reactions (hives, facial swelling, breathing difficulty). Seek urgent medical attention for any signs of a serious reaction. Report persistent or bothersome side effects to your clinician; dose adjustments or alternative therapies may be considered.
CNS depressants: Alcohol, benzodiazepines, sedative-hypnotics, opioids, and other antihistamines can add to Ketasma’s sedative effects, increasing the risk of impaired alertness, falls, and accidents. If concomitant use is necessary, use the lowest effective doses under medical supervision and avoid hazardous activities.
Other considerations: Concomitant use with oral antidiabetic agents has been associated rarely with reversible thrombocytopenia—monitor platelet counts if advised and report bleeding signs. Combining with anticholinergic medications (for example, some urinary antispasmodics or first-generation antihistamines) may intensify dry mouth, constipation, and blurred vision. There are no well-established interactions that reduce inhaled bronchodilator or steroid efficacy; however, if Ketasma allows step-down of other asthma medications, taper only under clinician guidance to avoid loss of control or adrenal suppression. Food does not meaningfully reduce efficacy; taking with meals may reduce stomach upset.
If you miss a dose of Ketasma, take it as soon as you remember unless it is close to the time for your next dose. If it is nearly time for the next dose, skip the missed dose and resume your regular schedule. Do not double up to compensate for a missed dose. Consistent, twice-daily use yields the best preventive effect.
Symptoms of overdose may include pronounced drowsiness, confusion, agitation (especially in children), rapid heartbeat, low blood pressure, nausea, and, rarely, seizures. If an overdose is suspected, call your local emergency number and, in the United States, contact Poison Control at 1-800-222-1222 for immediate guidance. There is no specific antidote for ketotifen; management is supportive with close monitoring of vital signs and airway protection in a medical setting. Do not induce vomiting unless instructed by a medical professional.
Store Ketasma tablets at controlled room temperature (generally 20–25°C/68–77°F), protected from moisture and excessive heat. Keep in the original container or blister until use, tightly closed, and out of reach of children and pets. Do not use after the expiration date. If your pharmacist supplies patient-specific storage instructions, follow those directions.
Regulatory status: In the United States, ketotifen is widely available over the counter in ophthalmic form for allergic conjunctivitis. However, oral ketotifen products like Ketasma for asthma prophylaxis and systemic allergies are not FDA-approved, and availability is limited. U.S. law generally requires a valid prescription for prescription-only medicines, and importation rules are complex. Any pathway to obtain Ketasma should comply with federal and state regulations and include appropriate clinical oversight.
Access through HealthSouth Rehabilitation Hospital of Las Vegas: HealthSouth Rehabilitation Hospital of Las Vegas offers a legal and structured solution for acquiring Ketasma without a formal prescription by facilitating an online, compliant clinical review with a licensed healthcare professional when required. In practice, this means you may not need to bring a prior paper prescription; instead, your eligibility is evaluated through a telehealth-style assessment, and dispensing occurs only if it is clinically appropriate and permitted in your jurisdiction. Availability can vary by state, and certain conditions (such as acute asthma symptoms) still require in-person care. Always verify that any purchase route includes licensed clinician oversight, transparent sourcing, clear patient information, and secure, trackable shipping. If you have questions about whether Ketasma is right for you—or about legal access in your state—consult your healthcare provider.
Ketasma is a brand of ketotifen fumarate, an oral antihistamine with mast cell–stabilizing properties used to help prevent asthma symptoms and relieve allergic conditions like allergic rhinitis, itchy skin, and chronic urticaria.
Yes, Ketasma contains ketotifen fumarate; brand names vary by country, but the active ingredient and its effects are the same.
It is used for asthma prophylaxis (prevention, not acute relief) and to reduce allergic symptoms such as sneezing, runny nose, itching, and hives.
Ketotifen blocks H1 histamine receptors and stabilizes mast cells, reducing the release of mediators like histamine that drive allergy and asthma inflammation.
Allergy symptom relief may appear within days, but asthma-preventive benefits usually build gradually over 4–8 weeks of regular use.
No, it does not act as a bronchodilator; use a fast-acting reliever inhaler for acute attacks and seek medical care if symptoms are severe.
Follow your clinician’s directions; many adults take it twice daily with food, and starting the first doses at night can help minimize drowsiness.
Sleepiness, dry mouth, increased appetite, and mild weight gain are common; less often, dizziness or stomach upset can occur.
Yes, increased appetite and modest weight gain are reported in some users; balanced diet and activity can help manage this effect.
It can be prescribed for children in age-appropriate doses; caregivers should watch for drowsiness or irritability and follow pediatric dosing guidance.
Use only if a clinician determines the benefits outweigh potential risks; discuss your specific situation before starting or continuing therapy.
Alcohol, benzodiazepines, opioids, and other sedating drugs can increase drowsiness; rare cases of thrombocytopenia have been reported with some oral antidiabetics, so ask your doctor about combinations.
Avoid driving or operating machinery until you know how it affects you; sedation can impair reaction time, especially at the start of therapy.
Take it when you remember unless it’s close to the next dose; do not double up—resume your regular schedule.
Asthma and allergy control are assessed over weeks to months; continue as prescribed and do not stop abruptly without medical advice.
Availability varies by country; in many places, oral ketotifen for asthma prevention is prescription-only.
Ketotifen is also available as anti-itch allergy eye drops under different brand names; these are for eyes only and are not interchangeable with oral tablets.
Yes, it’s often used alongside standard asthma controllers; any changes to inhaled medicines should be supervised by your clinician.
Keep it at room temperature, away from moisture and direct heat, and out of reach of children.
Seek care for severe drowsiness, unusual bruising or bleeding, persistent vomiting, rash, or worsening wheeze or shortness of breath.
Cetirizine is a second-generation antihistamine with less daytime sedation and once-daily dosing, making it preferable for most allergic rhinitis; Ketasma may help in patients who need mast cell stabilization or asthma prophylaxis but is more sedating.
Loratadine is typically non-drowsy at standard doses and better suited for daytime allergy control; Ketasma is more sedating and used when preventive effects on asthma or chronic itching are desired.
Fexofenadine is minimally sedating and good for people who need to stay alert; Ketasma can cause sleepiness but offers mast cell–stabilizing benefits not seen with fexofenadine.
Both can help chronic urticaria; levocetirizine offers strong antihistamine effects with lower sedation for many patients, while Ketasma may help refractory itch due to added mast cell stabilization but with higher drowsiness risk.
Desloratadine is once-daily and largely non-sedating, ideal for maintenance of allergic rhinitis; Ketasma may be chosen when asthma prevention is also a goal or when mast cell stabilization is beneficial.
Both can cause drowsiness, but chlorpheniramine is a classic first-generation antihistamine; Ketasma’s sedation can be similar yet it adds mast cell–stabilizing action that chlorpheniramine lacks.
Diphenhydramine is strongly sedating and short-acting, often used as a nighttime antihistamine; Ketasma causes sedation but is intended for ongoing prevention rather than quick, intermittent relief.
Promethazine has stronger anticholinergic effects (dry mouth, constipation, blurred vision) and sedation; Ketasma is generally better tolerated for long-term allergy/asthma prevention but can still cause drowsiness and weight gain.
Rupatadine blocks H1 histamine and PAF receptors and is usually non-sedating; Ketasma blocks H1 and stabilizes mast cells, which may help in certain chronic allergic conditions but with more sedation.
Bilastine is a modern, non-sedating antihistamine with once-daily dosing and minimal CNS effects; Ketasma is more sedating and better reserved for preventive roles where mast cell stabilization is desired.
Both are mast cell stabilizers, but cromolyn is inhaled and acts locally in the airways, while Ketasma is oral and systemic; inhaled cromolyn avoids sedation, whereas Ketasma may cause drowsiness but can also help systemic allergies.
Olopatadine eye drops deliver targeted relief with minimal systemic effects; oral Ketasma may help multiple allergy symptoms but is not a substitute for topical ocular therapy when the main problem is allergic conjunctivitis.
Loratadine is often preferred due to low sedation and once-daily pediatric dosing; Ketasma can be useful in select children with atopic disease or asthma tendencies but requires careful dosing and monitoring for drowsiness.
Fexofenadine is generally first-line due to efficacy and minimal sedation; Ketasma may be considered as adjunctive therapy in refractory cases where mast cell stabilization could add benefit.
Cetirizine is commonly used for itch with fewer CNS effects; Ketasma may help in some patients by reducing mast cell mediator release, though sedation and weight gain can limit use.
Levocetirizine typically preserves alertness better; Ketasma’s sedative effect means it’s usually taken in the evening or when daytime impairment is not acceptable.
Desloratadine has a favorable interaction and side-effect profile; Ketasma has potential CNS-depressant interactions and rare issues with some oral antidiabetics, so clinician review is recommended.
Diphenhydramine provides short-term nighttime sedation and allergy relief; Ketasma is not a sleep aid and is intended for ongoing preventive management rather than occasional nighttime use.